Abstract The lack of readily available biomarkers is a significant hindrance toward progressing to effective therapeutic and preventative strategies for Alzheimer’s disease (AD). Blood-based biomarkers have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging and cerebrospinal fluid biomarker approaches. Despite the fact that preanalytical processing is the largest source of variability […]
Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research.
May 1, 2015
Alzheimers Dement